Bellinger Andrew 4
4 · Verve Therapeutics, Inc. · Filed Sep 27, 2022
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-09-23$34.67/sh−6,632$229,905→ 19,997 total - Exercise/Conversion
Common Stock
2022-09-23$1.48/sh+20,000$29,600→ 26,629 total - Sale
Common Stock
2022-09-23$35.59/sh−13,368$475,803→ 6,629 total - Sale
Common Stock
2022-09-23$35.31/sh−36,798$1,299,304→ 9,831 total - Exercise/Conversion
Stock Option (right to buy)
2022-09-23−20,000→ 23,198 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2022-09-23$1.48/sh+40,000$59,200→ 46,629 total - Sale
Common Stock
2022-09-23$36.03/sh−3,202$115,380→ 6,629 total - Exercise/Conversion
Stock Option (right to buy)
2022-09-23−40,000→ 96,995 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (40,000 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), and (5) of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.26 to $36.15, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.88, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.92 to $36.15, inclusive.
- [F6]The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.